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On the current trajectory, over half of the adult pop-
ulation in the United States will be obese by 2030, and 
similar increments are likely to occur in other developed 
countries1,2. With its many related medical complica-
tions, obesity is challenging smoking and drinking as 
the number one contributor to morbidity and mortality 
worldwide. The prevalence of one of the most devas-
tating consequences of obesity, type 2 diabetes mellitus 
(T2DM), which is characterized as the progressive wors-
ening of insulin resistance and compensatory increases 
in insulin secretion, is increasing at similarly alarming 
rates. While T2DM is clearly a multifactorial and com-
plex disorder, there is no doubt that obesity-induced 
insulin resistance accelerates pancreatic islet exhaustion 
and thus the onset of T2DM3.
Intricate environmental and genetic factors are at the 
root of the modern-day obesity crisis. The unprecedented 
availability of inexpensive palatable, calorie-dense foods 
coupled with a decrease in occupational physical activity 
has created an obesogenic environment. Nonetheless, a 
considerable portion of the global population remains 
lean, highlighting innate genetic components that influ-
ence a person’s susceptibility to developing obesity. This 
genetic predisposition to obesity (and also to T2DM) is 
determined by the interaction of multiple risk genes that 
individually have only modest bearing4.
Unravelling this complex interaction of nature and 
nurture is pivotal to develop strategies to prevent, reverse 
or ameliorate the harmful effects of obesity and T2DM. 
To tackle these objectives, researchers rely on diverse ani-
mal models that span multiple species and strategic scien-
tific approaches. The first widely used animal model for 
metabolic research was the dog, with pioneering studies 
in the early 20th century including Ivan Pavlov’s Nobel 
Prize work (awarded in 1904) on gastric secretions and 
the later discovery of insulin by Frederick Banting and 
Charles Best (Nobel Prize in 1923)5. For the past 2 decades, 
research that has used small rodents, especially mice, has 
been at the forefront of scientific advancements on obesity 
and diabetes mellitus. For example, rodent studies led to 
the discovery of the central actions on energy balance of 
leptin6 and ghrelin7. In this Review, we highlight the advan-
tages and limitations of the most commonly used animal 
models of research on obesity and diabetes mellitus.
Human obesity — hallmark manifestations
Obesity is characterized by a pathological excess of body 
fat that results from a persistently positive energy bal-
ance8. Comorbidities directly associated with excess body 
fat include T2DM, certain cancers and cardiovascular 
diseases including hypertension, coronary artery disease 
and stroke9. More severe cases of obesity are associated 
with an increased incidence of sleep apnea10,11, asthma12–14, 
gallstones15, steatohepatitis16, glomerulosclerosis17, dyslip-
idaemia and endothelial dysfunction18,19. The metabolic 
complications linked to obesity are often attributed to 
systemic processes such as metabolic inflammation or 
cellular pathologies such as mitochondrial dysfunction20 
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Abstract | More than one-third of the worldwide population is overweight or obese and therefore 
at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more 
potent therapeutics are urgently required. This necessitates the continued use of animal models 
to discover, validate and optimize novel therapeutics for their safe use in humans. In order to 
improve the transition from bench to bedside, researchers must not only carefully select the 
appropriate model but also draw the right conclusions. In this Review, we consolidate the key 
information on the currently available animal models of obesity and diabetes and highlight the 
advantages, limitations and important caveats of each of these models.
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and/or stress of the endoplasmic reticulum due to lipo-
toxicity19,21. Under conditions of obesity, the lipid stor-
age capacity of the adipocytes is exceeded, resulting in 
adipocyte-derived fatty acids and cytokines leaking into 
the circulation22. Harmful lipid species then accumu-
late in ectopic tissues and cause local inflammation that 
contributes to the development of endothelial dysfunc-
tion, non-alcoholic fatty liver disease and insulin resist-
ance23–25. In addition to fatty acids and cytokines, altered 
secretion of other adipokines (such as adiponectin) or 
lipokines also contribute to metabolic impairments in 
other tissues such as the liver or the pancreas26,27.
Reliable methods to assess both the quantity of body 
fat depots and the distribution of body fat are availa-
ble for humans as well as for animal models. Methods 
used in the clinic to analyse total body fat composition 
include a measurement of height with weight to calculate 
a BMI in addition to waist circumference and skinfold 
thickness measurements. Hydrostatic weighing, air dis-
placement plethysmography, bioimpedance analysis, 
dual- energy X-ray absorptiometry (DXA) and quantita-
tive magnetic resonance (qMR) are accurate and precise 
techniques to assess total body fat but are more costly 
than anthropomorphic measuring. Ultrasonography is 
an approach that allows clinicians to measure the thick-
ness of subcutaneous fat, muscle and intra-abdominal 
depth. A precise assessment of body fat distribution can 
be obtained from CT and MRI28.
Methods are also available to measure body fat in ani-
mal models (BOX 1). Investigators can dissect fat depots 
at termination of an experiment and weigh them. In 
addition, measurements of total body composition 
at termination can be made by whole-body chemical 
carcass composition analysis. While these methods are 
inexpensive, instruments also exist to measure the total 
body composition of living animals, allowing for longi-
tudinal measurements and calculations of change. DXA 
provides a noninvasive approach to assess body fat and 
lean tissue contents. Data derived from DXA are vali-
dated using chemical analysis29. A DXA scan, however, 
can be conducted on only an anaesthetized animal and 
will likely disrupt feeding on those days. qMR is another 
precise method that compares well to chemical analysis 
methods30. qMR is rapid and does not require the animal 
to be restrained, avoiding use of anaesthesia. MRI can 
noninvasively be used to obtain separate fat and water 
images with quantification in anatomically distinct fat 
depots with animal models of obesity31. However, as 
with DXA, the animal must be anaesthetized during 
the measurement.
Successful weight-loss interventions must decrease 
food intake or increase energy expenditure — ideally 
both together. Although successful changes in lifestyle 
with a decrease in calorie intake and increased physical 
activity can meet these criteria in humans, such lifestyle 
changes typically result in only modest weight loss of 
3–4% after 4 years32. Pharmacotherapy as an adjunct to 
lifestyle changes can further increase weight loss, but the 
efficacy of previous or current weight-loss pharmaco-
therapies is also only moderate, with weight loss typically 
in the range of 6–8% after 1–4 years32–35. The development 
Key points
• Development of safe and potent therapeutics is required to combat the obesity and 
diabetes mellitus pandemic
• Animal models remain indispensable for discovering, validating and optimizing novel 
therapeutics for their safe use in humans
• To improve the transition from bench to bedside, researchers must select the 
appropriate models, beware a myriad of confounding factors and draw appropriate 
conclusions
• Experimental procedures and conditions should be accurately detailed to improve 
the reproducibility and translation of findings in preclinical animal models
• Different animal models, ranging from non-mammalian models to non-human 
primates, each have distinct advantages and limitations
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of novel pharmacotherapies with improved efficacy and 
sustained action is therefore a major challenge of global 
priority. In this regard, one promising avenue is based 
on recent advances in the engineering of unimolecu-
lar multiagonist peptides that simultaneously activate 
several key metabolic pathways, each having beneficial 
effects on metabolism36–39. Several of these multiago-
nist peptides are currently in clinical evaluation40–42. 
The development of these and other novel pharmaco-
logical options to tackle the global ‘diabesity’ pandemic 
requires a solid understanding of the complex interac-
tions of central and peripheral signal mechanisms that 
regulate systemic energy and glucose metabolism.
Preclinical animal models have provided considera-
ble valuable information about obesity and T2DM (FIG. 1). 
Despite constant improvements and refinements in cell-
based applications, careful metabolic assessment of com-
pound effects in in vivo models is vital before drugs can 
be considered for clinical evaluation and commerciali-
zation. The choice of a specific method to measure body 
composition depends on the need for accuracy, precision, 
convenience, cost and safety. Of note, before selecting any 
of the animal models described in this Review, research-
ers could consider the method or methods that will be 
used to measure body composition, if that is an aim of 
the study.
Zebrafish, Caenorhabditis elegans and Drosophila
Two major advantages of using non-mammalian experi-
mental organisms (and particularly metazoans) are their 
short lifespan, which expedites quantification of long-
term and transgenerational consequences of obesity 
and diabetes, and the fact that investigators can perform 
high-throughput analyses on such organisms, as exem-
plified by the availability of whole-genome RNA interfer-
ence (RNAi) libraries. For example, genome-wide genetic 
screens have identified novel candidates pertinent to the 
control of body fat accumulation and function43,44 in 
the nematode Caenorhabditis elegans45 and in the fruitfly 
Drosophila melanogaster46. Dietary induction of obesity 
is achieved in the roundworm C. elegans44,47, in the fruit-
fly D. melanogaster48 and in the zebrafish Danio rerio49. 
While all three of these species have been subjected to 
experimental calorie restriction, only Drosophila has 
been successfully exposed to different sources of macro-
nutrients50,51. Food cue sensing and satiety are linked 
to the amphid neuron ASI and to transforming growth 
factor-β (TGFβ) signalling in C. elegans52,53, resembling 
findings in mice54. Neuronal circuits controlling body 
fat storage have also been established in Drosophila55. To 
date, investigators have not identified many of the hor-
mones known to regulate lipid storage in mammals in 
non-vertebrate species such as C. elegans and Drosophila, 
but the vertebrate zebrafish has mammalian-like ghre-
lin56 and leptin57 activity. Consistent with the latter, over-
expression of endogenous agouti-related protein (Agrp) 
causes obesity in zebrafish58.
At the intersection of energy storage and glucose 
metabolism, glucagon signalling seems to exist in 
Drosophila59 and zebrafish60, but published evidence in 
nematodes is lacking. By contrast, extensive evidence 
exists for orthologous insulin and insulin-like growth 
factor I (IGF-I)-like signalling peptides in all three spe-
cies61–63. Consistent with these findings, insulin resistance 
can be induced in Drosophila by activating forkhead box 
protein O (Foxo)64 or by a high-calorie diet65. In non- 
mammalian metazoans, several different cell types includ-
ing neurons and hypodermic cells produce insulin and 
IGF-I-like signalling peptides.
Box 1 | Methodologies to measure body composition in models of obesity
Body weight 
• Whole animal body mass
 - Equipment: balance
 - Advantages: quick; accurate; no anaesthesia; suitable for linear measurements
 - Disadvantages: no assessment of body composition; low precision of live weight
Organ weight
• Target organ mass
 - Equipment: balance
 - Advantages: quick; accurate; tissue specificity
 - Disadvantages: precision depends on standardized dissection of organs or tissue 
depots; terminal measurements only; not for whole-body assessment
Carcass analyses 
• Chemical analyses of the whole body
 - Equipment: oven; grinder; specialized instruments
 - Advantages: whole-body end points; total fat values considered the gold standard; 
provides ash mass as a readout for bone mineral density (BMD); whole-body water 
content
 - Disadvantages: impractical for large animals; low precision; terminal measurements 
only; provides total protein content rather than total lean mass
Dual-energy X-ray absorptiometry (DXA)
• Absorption of X-ray beams by tissues of different densities
 - Equipment: DXA instrument
 - Advantages: whole-body end points; BMD values considered the gold standard; 
provides total fat and lean mass; suitable for linear measurements; accurate; precise
 - Disadvantages: anaesthesia (disrupts feeding on procedure and day); 
time-consuming scan; exposure of animal and experimenter to X-rays
CT
• Absorption of X-rays by tissues of different densities by use of quantification software
 - Equipment: CT instrument
 - Advantages: whole-body end points; BMD values considered the gold standard; 
cortical and trabecular bone recognition; provides subcutaneous and visceral fat 
quantification; suitable for linear measurements; accurate; precise; quick
 - Disadvantages: anaesthesia; exposure of animal and experimenter to X-rays; low 
accuracy for lean mass
NMR relaxometry or quantitative magnetic resonance (qMR) 
• NMR spectra of tissues
 - Equipment: whole-body NMR
 - Advantages: whole-body end points; provides whole-body fat, lean and free water 
mass; suitable for linear measurements; requires no anaesthesia; accurate; precise; 
quick
 - Disadvantages: No bone data; does not distinguish subcutaneous from visceral fat; 
lean mass is calibrated to lean chicken muscle
MRI
• NMR in a strong magnetic field
 - Equipment: MRI instrument within a room shielded for powerful electromagnetic 
forces
 - Advantages: high-resolution anatomical images based on water and fat distribution; 
quantification of total fat and lean mass; suitable for linear measurements
 - Disadvantages: anaesthesia (disrupts feeding on procedure and day); scan is 
time-consuming
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Amphid neuron
Sensory neurons found in  
the anterior head region of the 
nematode Caenorhabditis 
elegans.
Dedicated insulin-producing cells have been identi-
fied in zebrafish but not in C. elegans or Drosophila60,66. 
Similar to what occurs in mammals, β-cell differentia-
tion from common precursors in zebrafish requires both 
Notch and pancreas transcription factor 1 (Ptf1) signal-
ling67–70. Terminal differentiation has been obtained 
with a set of FDA-approved compounds71 as well as 
with a bacterial protein named β-cell expansion factor 
A (BefA) that is also present in the human gut micro-
biota72. Ablation of β-cells in zebrafish66 and ablation of 
insulin- producing neurons in Drosophila73 cause hyper-
glycaemia — a comparable diabetes-like state has not 
been induced in C. elegans. Nevertheless, nematodes are 
used to study reductions in lifespan induced by glucose 
toxicity47,74 as well as the induction of diabetic neuro-
pathy via formation of methylglyoxal and advanced 
glycated end products74.
Studies have investigated cardiac function75 and 
memory impairment76 in metabolically impaired 
Drosophila and zebrafish, respectively. Collectively, 
non-mammalian species possess multiple, but not all, 
pathways of body mass control and energy balance found 
in mammals, exhibit conserved features of insulin- like 
signalling and secretion, develop diabetes-like states 
when exposed to genetic or environmental (particularly 
nutritive) perturbations and are consequently valuable 
tools to initiate or refine the conceptual basis of more 
detailed analyses in higher organisms.
Rodent models
Small rodents, including rats and especially mice, are 
the most widely used preclinical animal model to study 
metabolic disorders77–80. Being mammals, the physiology 
of mice and rats is closer to that of humans than non- 
mammalian species. In recent decades, the popularity of 
mouse models has surged to the point that currently ~60% 
of all preclinical animal research is conducted in Mus 
musculus81. This surge in usage can be explained in part 
by the many molecular genetic tools available to engineer 
targeted or non-targeted mutations, from single nucleo-
tide exchanges to chromosomal rearrangements, for gene 
functional assays in mice. Additionally, standardized 
Nature Reviews | Endocrinology
Non-human primate models
• Metabolic physiology and anatomy similar to humans
• Genetic identity close to that of humans (~99% similarity)
• Translational relevance
• Possible to conduct blood sampling, endoscopy and serial 
laparoscopic biopsies
Throughput
• Costly to maintain, limited approved facilities and 
ethical issues
• Long life cycle and uniparity
Large animal models
• Similar size and shape to a human with 
human-relevant physiology
• Available genetic tools similar to those 
available for rodents (pig) and multiparity
• Chronic cannulation possible, and stress 
can be reduced with training
• Pharmacokinetics similar to humans
• Pancreas and islet architecture similar 
to humans
• Costly and specialized facilities required
• Long life cycle
Non-mammalian models
• Short life cyle (except zebra ﬁsh)
• Whole-genome RNAi library available
• Obesity-like and T2DM-like models
• Low maintenance cost
• Conserved biochemistry
• Distinct physiology and anatomy Rodent models
• Numerous models of obesity and T2DM
• Tools available for genetic manipulation
• Metabolic phenotyping technology available
• Cost-eﬀective and multiparity
• Pancreatic islet architecture distinct from humans
• Monogenic models are not representative of most human diseases
   Relevance to hum
an physiology
Figure 1 | Key advantages and disadvantages of different classes of animal models used in obesity and diabetes 
research. Obesity and type 2 diabetes mellitus (T2DM) research spans a wide range of animal models that have distinct 
advantages and shortcomings. As a general rule, non-mammalian models have the advantage of low maintenance cost,  
a short life cycle and the availability of diverse gene-editing tools. However, their translational value is limited given their 
distinct anatomy and physiology. By contrast, the physiology of large animal models including the dog and the pig, and 
especially that of non-human primates, closely resembles human physiology. However, the trade-off is that these species 
have high maintenance costs and especially long life cycles. Further, because each dam produces only a low number of 
offspring in her lifetime, these models are undesirable for large-scale, time-efficient experiments. Small rodents and 
especially the laboratory mouse represent a good compromise between throughput and translational physiology. Their 
physiology is closer to that of humans than non-mammalian models, and their small size, high fecundity and short life 
cycle, coupled with the relative ease of editing their genome, explain their popularity. RNAi, RNA interference.
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methods and devices for phenotyping mice are abundant 
and continue to be improved. Finally, mice are small in 
size, have reproductive outputs of approximately 6–12 
pups (depending on the respective mouse strain), have 
a moderately short reproductive cycle, reaching sexual 
maturity within 4–8 weeks of birth, and have a gestation 
period of just 3 weeks — all these characteristics make 
mice an economical choice for researchers. In the sections 
below, we consolidate key aspects and considerations for 
performing and analysing rat and mouse studies under 
the umbrella of obesity and diabetes research (TABLE 1).
Diet-induced obesity and insulin resistance
Diet-induced obesity has considerable face validity with 
human obesity82 and consequently is a widely used par-
adigm to study the interaction of diet and genes in mani-
fest obesity and insulin resistance. In a typical procedure, 
rats or mice are given free access to calorie-dense foods 
highly enriched in fats (also known as high-fat diets 
(HFDs)) or other ingredients of interest, such as sugar 
or sodium, and the progression of obesity and diabetes 
as well as their related comorbid sequalae is monitored. 
For example, assessments of the effects of certain drugs 
or genetic manipulations on the development of obesity 
(or reversal of obesity) or on the impairment of glucose 
metabolism may be superimposed on investigations 
into how obesity progresses in response to different 
diets. Although the diet-induced obesity (DIO) model 
recapitulates large parts of the pathogenesis of human 
obesity, including the slow progressive weight gain and 
the secondary development of insulin resistance, it does 
have shortcomings. DIO studies are time-consuming 
and costly, and although the proposition seems straight-
forward, numerous factors (described below) influence 
the outcome and interpretation of the results and their 
translational value.
Strain. Inbred mouse strains have genetic differences 
that influence their susceptibility to DIO and diabetes. 
The inbred C57BL/6J mouse strain is widely used as 
a model for DIO because it is prone to develop severe 
obesity, elevated adiposity, glucose intolerance and 
moderate insulin resistance83,84. Other inbred strains, 
including SWR/J and A/J mice, are less susceptible 
to DIO and related complications85–87, making them 
especially intriguing models to study human obesity 
resistance.
By measuring insulin resistance as defined by HOMA, 
one report demonstrated the staggering breadth of strain 
variation by surveying over 100 unique inbred mouse 
strains after 8 weeks on a high-fat, high-sucrose diet88. 
The authors noted a remarkable 63-fold and 37-fold var-
iation in the degree of insulin resistance between males 
and females across the strains, respectively88. Because of 
these findings, researchers must carefully optimize their 
strain selection (and other experimental factors) on the 
basis of their specific research questions. For instance, 
if a study is investigating the effects of a drug on overt 
diabetes end points, then the DIO C57BL/6J model is 
not the ideal choice because this strain rarely develops 
frank hyperglycaemia and/or islet atrophy when fed an 
obesogenic diet89,90. By contrast, the rather closely related 
but distinct C57BL/6N strain91 develops hepatosteato-
sis, hyperglycaemia and hyperinsulinaemia following 
3 weeks on a HFD92.
The susceptibility of rats to DIO also depends on 
the respective strain93. The most prevalently used lab-
oratory rat strains (Sprague Dawley, Wistar and Long–
Evans) are outbred, meaning that they have considerable 
genetic variation, which investigators should take into 
account when determining sample size. Sprague Dawley 
rats, for example, exhibit a wide distribution in HFD-
induced body weight gain94, reminiscent of the genetic 
heterogeneity of the human condition.
The choice of inbred strain is also important when 
working with genetically modified mice. 129/Sv and 
FVB mice are the preferred strains in which to gener-
ate knockout models, and C57BL/6J mice are favoured 
for metabolic studies; however, ongoing large-scale pro-
jects aimed at mutating every protein-coding gene in 
the mouse are underway in C57BL/6N embryonic stem 
cells95. Investigators have already used this resource to 
produce mouse lines and to systematically phenotype 
them for a broad range of tests including hallmark param-
eters for diabetes and metabolism96. The ultimate aim of 
the project is to have a knockout mouse line for every gene 
in the genome (see: www.mousephenotype.org) to search 
for phenotyping data and availablemouse lines97.
In contrast to these large multicentre studies, which 
have been performed on an inbred background, mixed 
strains resulting from insufficient backcrossing respond 
differentially in metabolic studies98–101, and backcross-
ing for at least 8–10 generations is considered minimal 
to establish a sufficiently homogenous background. 
Investigators should confirm a genetic background by 
single nucleotide polymorphism (SNP) panel analyses, 
which are commercially available. As subtle genetic drift 
can influence experimental results, littermates are most 
often the best controls in metabolic research. While 
experimental control is paramount in order to obtain 
conclusive results, differences due to genetic drift and 
strain variation are informative, considering the complex 
polygenic nature of obesity in humans.
Sex. Male mice are more susceptible to DIO, whereby 
they develop obesity sooner and to a greater extent than 
female mice102–104. By contrast, in rats, DIO progression 
is more comparable between males and females93,94,105. 
Sex differences in mice and rats for phenotypes of diet- 
induced insulin resistance and glucose intolerance are 
more pronounced, with male mice and male rats being 
the most affected105–109. This sex difference largely per-
sists in most rodent models of T2DM and the Zucker 
Diabetic Fatty (ZDF) rat provides one striking example. 
On normal rodent chow diets, male ZDF rats develop 
severe hyperglycaemia (~400 mg/dl) and hypoinsulinae-
mia (~1,000 pmol/l) by 4 months of age. By contrast, and 
rather remarkably, female ZDF rats maintain normal lev-
els of glucose (~100 mg/dl) and insulin (~5,000 pmol/l) 
throughout their life, despite developing obesity to a 
similar extent as the males. Sexual dimorphism in gly-
caemia also translates to humans. Data suggest that 
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women are generally less likely to suffer from diet- 
induced consequences of T2DM than men110–113. This 
finding is reflected in the global prevalence of T2DM, 
with women being less frequently diagnosed with 
T2DM than men114. Obesity, however, is more prevalent 
among women115. Sexual dimorphism in obesity com-
plications is linked to the gonadal hormones (testos-
terone versus oestradiol and progesterone) and to their 
differential effect on fat distribution. Central adiposity, 
especially visceral fat, is detrimental to health, while fat 
accretion in the lower body in the form of subcutaneous 
fat might actually bestow protective effects116. Although 
the mechanisms of these depot-specific effects remain 
poorly defined, women and female rodents have more 
subcutaneous and less visceral fat than their male coun-
terparts117,118. Removing the ovaries, thereby ablating 
endogenous oestradiol and progesterone production, 
masculinizes fat distribution and increases the sus-
ceptibly to diet-induced insulin resistance in female 
rats and mice103,119,120. In addition, evidence indicates 
that non-gonadal sex-chromosome-specific factors 
also have a role in the manifestation of metabolic 
differences. Using a mouse model known as the four core 
genotypes121, one group found that sex chromosomes, 
independent from gonadal sex, have a role in adiposity, 
feeding behaviour, the development of fatty liver and 
glucose homeostasis121. Potential mechanisms respon-
sible for the effects of sex chromosomes on the suscepti-
bility to DIO and diet-induced insulin resistance might 
include differential gene dosage from X chromosome 
genes that escape inactivation and/or distinct genomic 
imprints on X chromosomes inherited from the mother 
or father122–124.
The take-home message is that sex differences are 
the norm rather than the exception in obesity research. 
Analyses of genome-wide association studies (GWAS) 
support this notion, highlighting a sex-specific genetic 
blueprint that underpins the susceptibility to obesity 
and diabetes mellitus88,125. Therefore, researchers should 
heed the recent NIH initiative126 to investigate (and 
report) both sexes in preclinical biomedical research. 
Currently, there is a lopsided reliance on using male 
rodents in preclinical research127, especially in drug 
studies. Female rodents are explicitly avoided because 
Table 1 | List of selected rodent models potentially useful in obesity, insulin resistance and type 2 diabetes mellitus research
Strain or method Species Diet Obesity Hyperglycaemia IR T2DM Dyslipidaemia Pathologic islet 
changes
Polygenic
C57BL/6J Ms HFD + – + – + –
SWR/J Ms HFD – – – – + –
A/J Ms HFD + – – – + –
C3H/HeJ Ms HFD + – + + + –
DBA/2J Ms HFD + – + – – –
NZO Ms CHO ++ + ++ + + +
TALLYHO/Jng Ms SD, HFD + + ++ + ++ +
DIO-sensitive Sprague 
Dawley
Rat HFD + – + – + –
DR Sprague Dawley Rat HFD – – – – – –
UCD-T2DM Rat SD, HFD + + ++ ++ + +
Sand rat Gerbil SD, HFD + – + + + +
Goto–Kakizaki Rat SD, HFD – + + + + +
Monogenic
C57BL/6J–ob/ob Ms SD, HFD ++ – ++ – + –
C57BLKS/J–db/db Ms SD, HFD ++ + ++ + ++ +
Otsuka Long–Evans 
Tokushima Fatty
Rat SD, HFD + + + + + +
fa/fa Rat SD, HFD ++ + ++ – + –
Zucker Diabetic Fatty Rat SD, HFD ++ ++ ++ + ++ ++
Koletsky Rat SD, HFD ++ – + – + –
Experimental
Low-dose 
streptozotocin
Ms, Rat HFD + + + + + +
VMH lesion Ms, Rat SD, HFD ++ – + – + –
–, absent; +, mild; ++, severe; CHO, carbohydrate enriched diet; DIO, diet-induced obesity; DR, diet resistant; HFD, high-fat diet; IR, insulin resistance; Ms, Mouse; 
SD, standard diet; T2DM, type 2 diabetes mellitus; VMH, ventromedial hypothalamus.
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Four core genotypes
A mouse model system that 
dissociates the effects of the 
gonadal sex (testes or ovaries) 
from the effects of the sex 
chromosomes (XX or XY)121.
of a widespread, albeit unsubstantiated128, assumption 
that the female oestrous cycle induces undesirable exper-
imental variability; however, controlling for the oestrous 
cycle phases is of course important. In addition, males 
are preferred for their more pronounced disease phe-
notypes; yet, the human obesity and T2DM crises affect 
both men and women. Clearly, interventions that aim 
to prevent or reverse obesity and/or treat T2DM should 
thus be tested in both sexes in order to improve their 
translational value. By ignoring sex, we also risk discard-
ing promising drug candidates, on the basis of their per-
formance (or lack thereof) in males only, that potentially 
benefit females.
Age. Age is another factor that has a considerable effect 
on outcomes in obesity and T2DM research. In humans, 
body weight increases with age and peaks at ~55 years 
in both men and women. Ageing per se is associated 
with a redistribution of both the fat-free mass and the 
fat mass, with the latter increase starting at ~30 years 
of age129. Intramuscular and intrahepatic fat are par-
ticularly increased in older persons, and this increase 
has been linked to insulin resistance130. Partially on the 
basis of these changes, ageing has been proposed to be 
an independent determinant of glucose tolerance, which 
progressively worsens with age131,132.
Ageing likewise affects metabolic parameters in 
rodents. Analogous to what occurs in humans, the body 
weight of the C57BL/6J mouse, the most commonly 
used mouse strain for metabolic studies, increases with 
age, peaking at ~9 months133, and older C57BL/6J mice 
(22 months) have reduced lean mass and increased fat 
mass compared with young 3-month-old mice134. In 
both rats and mice, fasting glucose levels are mostly sta-
ble throughout life, but whereas glucose tolerance gener-
ally worsens with age in rats, mice are less affected135–140. 
In fact, 2-year-old male C57BL/6J mice were signifi-
cantly more glucose tolerant than their 5-month-old 
counterparts138. Consistent with these findings, glucose- 
stimulated insulin release from the pancreas decreases 
with age in rats, but not in mice137,138.
Another important consideration is age at the begin-
ning of a dietary intervention study. If, for example, mice 
are put on a HFD at too young of an age (<8 weeks, in 
our experience), the subsequent development of obesity 
and adiposity is not particularly pronounced141.
Diet. Minor dietary differences can greatly affect met-
abolic parameters and experimental outcomes. For 
example, in rats, dietary fats from an animal source, 
such as lard, have a more pronounced effect on adipos-
ity and insulin resistance than vegetable fats142. Even 
subtle modifications, such as changes in the ratio of 
unsaturated to saturated fatty acids143 and the physical 
form of the diet (liquid versus solid)144,145, lead to dif-
ferent DIO outcomes. For example, the fat source used 
for the preparation of HFDs is the critical element that 
determines whether germ-free mice are resistant or sus-
ceptible to DIO146–148. Lastly, even the texture and hard-
ness of the food pellets must be considered. One study 
showed that mice fed on a powdered form of a low-fat 
diet spontaneously developed excess fat149. Therefore, 
taking into account these data, part of the DIO response 
might depend on altered texture rather than modifica-
tion of macronutrient composition, as the pellets used in 
HFDs are usually softer than those used in the respective 
control diets.
The aforementioned factors highlight the impor-
tance of standardizing diets and accurately detailing diet 
composition and administration. Experimental diets are 
composed of defined purified raw materials and should 
guarantee that nutrient composition is reproducible in 
each production lot. Researchers must also take care 
to select the proper control diets if the primary goal 
is to assess the effects of specific dietary components. 
For example, grain-based chow control diets are all too 
frequently compared with purified experimental HFDs, 
although the adjoining caveats are known150. These chow 
diets are likely to vary in composition by batch, season and 
vendor. Variability in non-nutritive dietary components, 
such as soluble fibre content and plant- derived phyto-
estrogens, affects the progression of DIO and metabolic 
disease, even affecting behavioural traits151,152.
Another consideration is that humans consume 
~30% of their daily calories from fat. This fat intake is 
remarkably consistent across age and BMI153 and lower 
than the 40% to 60% calories from fat used in many 
preclinical rodent studies of DIO. In our opinion, the 
translational value of results obtained with exceptionally 
HFDs, with nearly 80% calories from fat, is questionable. 
The metabolic endotoxaemia hypothesis, which states 
that high dietary fat intake impairs the gut barrier, is 
largely based on data from dietary interventions studies 
in mice that received 78% of their daily calorie intake 
as fat in an essentially carbohydrate-free diet formula-
tion154. Follow-up studies have shown that the proposed 
effect of HFD consumption on gut barrier integrity 
largely depends on housing conditions and bacterial 
colonization of the gut155,156.
A rise in sugar consumption is linked to the human 
obesity crisis157,158. With its high energy density and 
palatability, sugar easily facilitates a positive energy bal-
ance. Further, common sugar is composed of large parts 
of fructose, which exacerbates obesity complications 
such as liver disease159,160. Mice with access to fructose- 
supplemented water have increased adiposity compared 
with mice with access to glucose water, despite a com-
parable calorie intake161. Compared with what occurs 
on a HFD, body weight gain and adiposity observed in 
rodents on high-sugar diets are often less pronounced, 
but glycaemic control is equally negatively affected162,163. 
Sugar can also elicit neurochemical changes reminiscent 
of addictive drugs164.
Most experimental obesity-inducing diets lack the 
complexity and variety of the human diet. Moreover, 
rodent diets are typically pelleted for easy handling and 
weighing. The absence of dietary variety might explain 
why rodents often do not exhibit pronounced or per-
sistent hyperphagia when fed such diets165. This find-
ing is supported by the observation that mice largely 
overeat during the first days upon transition from the 
standard low-fat diet to a more palatable HFD but then 
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Envirotype
Factors that are exogenous to 
an organism.
progressively reduce their energy intake approaching the 
levels of animals fed the control diet166. The cafeteria diet, 
in which rodents have free access to several different pal-
atable high-energy ‘junk’ foods (in addition to regular 
chow and water)167, is an alternative approach to better 
mimic the hedonic hyperphagia168 that is observed in 
humans who are obese169. Consequently, compared with 
a HFD, the cafeteria diet promotes more pronounced 
weight gain and more severe diabetic symptoms167.
Epigenetic inheritance of diet-induced obesity. The 
accurate description and standardization of experi-
mental manipulation of the envirotype pose one major 
challenge for improving the mouse as a model system 
for meaningful obesity research170,171. Whether traits 
acquired during lifetime are passed on to the progeny 
via sperm and oocyte has been discussed but remains 
controversial172. Studies in rodents conducted under 
conditions of natural fecundation found that parental 
HFD feeding propagates obesity and glucose intolerance 
in their offspring173–179. With natural fecundation, how-
ever, factors such as the in utero environment, lactation 
and parental micro biomes, as well as behavioural dif-
ferences, confound the interpretation. By using healthy 
surrogate mothers to carry zygotes from in vitro ferti-
lizations with sperm and oocytes from parental mice 
that were fed either a low-fat diet or a HFD, one group 
elegantly circumvented the confounding factors and 
clearly demonstrated epigenetic germline inheritance of 
DIO and insulin resistance180. This finding is consistent 
with epidemiological data in humans demonstrating that 
an offspring’s BMI is associated with the degree of paren-
tal obesity181–183, whereas diminished glucose tolerance is 
more prominently associated with maternal rather than 
paternal impaired glycaemic control184.
Changes in the gametes’ transcriptomes, proteomes 
and metabolomes as well as characteristic marks in their 
genomic methylomes are potential candidates for the 
epigenomic information that transmits the acquired met-
abolic phenotype. Studies indicate that micro injection of 
specific sperm-derived small RNAs into zygotes can elicit 
persistent gene transcriptional effects and contribute to 
the metabolic phenotype in the offspring generation185–187. 
In contrast to genetic changes in the sequence of the DNA, 
such epigenetic changes can be reversed by environmen-
tal factors or nutritional supplements188. For example, the 
transgenerational effect of in utero exposure to a HFD 
can be reversed by a normal diet for three generations189. 
Interestingly, the authors of the study noted that histone 
modifications in the respective gene promoters accom-
panied changes in the expression levels of leptin and 
adiponectin in this in utero exposure model. The molec-
ular mechanisms that increase, maintain or diminish 
epigenetic signatures throughout multiple generations 
following different dietary exposures remain unclear. 
Researchers, however, should take care to be aware of 
the age and health (and dietary) status of the parent gen-
eration, as these factors could confound findings and/or 
results, such as the development of obesity in the ani-
mals of interest — this point emphasizes why littermate 
comparisons are best for most experiments.
Genetic rodent models
Spontaneous and targeted monogenic models. In 
the 1960s, Coleman and colleagues at the Jackson 
Laboratory discovered and isolated two stocks of 
mutant mice — the mildly diabetic but severely obese 
(ob) stock and the more moderately obese but severely 
diabetic (db) stock190–192. In now iconic parabiosis stud-
ies, researchers surgically joined mice from the ob stock 
with mice from the db stock, which resulted in ob mice 
rapidly losing weight, while the parabiosis had no effect 
on the db mice192. These findings suggested the presence 
of a hitherto unknown circulating factor (and a corre-
sponding sensor of that factor) that is essential in the 
regulation of energy metabolism and food intake. More 
than 2 decades later, through positional cloning of a gene 
that at the time was referred to as Ob but now is known 
as Lep, leptin was identified as the circulating factor6, 
igniting an explosion of research into the genetic causes 
of obesity. Subsequent work identified numerous genes 
that function in the hypothalamic leptin–melanocortin 
feeding pathway, including Lepr, Mc4r, Pomc and Pcsk1. 
Each of these genes has been functionally studied in 
gene-knockout mice and found to affect energy intake 
and expenditure and thus control body weight193. In 
addition, several of these genes are affected in human 
monogenic obesity syndromes194.
Investigators have intensely studied ob and db mice 
for decades, and to this day, they are used as preclini-
cal models. The leptin-null ob/ob mouse has a sponta-
neous mutation in Lep that precludes the secretion of 
bioactive leptin. The db/db mouse has a defect in lep-
tin signal reception, which is caused by a spontaneous 
mutation in Lepr. Remarkably, and often forgotten, when 
these mice are on the same genetic background, a lack 
of leptin production (ob/ob) or lack of leptin sensing 
(db/db) elicits nearly identical phenotypes195. 
Traditionally, however, ob/ob mice are maintained on a 
C57BL/6J genetic background, and the db/db mice are 
maintained on a C57BLKS/J genetic background. This 
difference in background is what imparts the pheno-
typic differences of severe obesity (ob/ob) versus severe 
diabetes (db/db)195 that were the inspiration for the 
nomenclature.
On the C57BL/6J genetic background, leptin-null 
ob/ob mice exhibit early-onset obesity that is promoted 
by hyperphagia and reduced energy expenditure196, as 
non-shivering thermogenesis of the brown adipose tis-
sue is reduced197,198. Additionally, ob/ob mice develop 
hyperinsulinaemia, mild hyperglycaemia and insulin 
resistance. These manifestations are likely secondary 
to the obesity. In addition, ob/ob mice are infertile199, 
have increased circulating corticosterone levels, suffer 
from hypothyroidism200 and have insufficient growth 
hormone (GH) levels, which results in stunted linear 
growth201. On the C57BLKS/J background, ob/ob mice 
suffer from pronounced diabetes mellitus marked 
by severe hyperglycaemia and atrophy of pancreatic 
islets202, leading to premature death202. Treatment with 
recombinant leptin normalizes all apparent complica-
tions in ob/ob mice203, as well as in humans with leptin 
deficiency204.
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Leptin-receptor-deficient db/db mice on the 
C57BLKS/J background largely recapitulate the obesity 
phenotype of the ob/ob mouse. The nomenclature of db 
(that is, diabetic) stems from the original observation of 
marked hyperglycaemia in these mice. db/db mice are 
hyperphagic and have reduced energy expenditure, lead-
ing to early-onset obesity195. They are also hypothermic, 
have decreased linear growth owing to GH deficiency and 
are infertile195, and leptin levels in db/db mice are markedly 
elevated205. Hyperinsulinaemia can be detected as early as 
10 days of age, and insulin levels continue to increase until 
3 months of age. The hyperinsulinaemia is accompanied 
by hyperplasia and hypertrophy of the pancreatic β-cells. 
After 3 months, levels of insulin in db/db mice drop pro-
foundly, which is concomitant with the atrophy of β-cells. 
Consequently, marked and sustained hyper glycaemia 
with blood glucose values >400 mg/dl promotes prema-
ture death around 5–8 months of age. However, the 
db/db model does not capture all the diabetic complica-
tions observed in the human disease. Vascular and reti-
nal complications, for example, are rarely documented in 
db/db mice, likely because of the dramatically shortened 
lifespan. Notably, db/db mice on a C57BL/6J background 
exhibit only mild diabetic symptoms and a normal 
lifespan, despite marked obesity78,79,195.
Analogous to the db/db mouse model, there are 
rat models with spontaneous defects in leptin signal 
reception. The obese Zucker rat has a defective lep-
tin receptor; a missense mutation in Lepr results in 
the receptor becoming trapped intracellularly, leading 
to blunted leptin signal transduction206,207. The Koletsky 
rat, also known as the spontaneously hypertensive 
obese (SHROB) rat, lacks a functional leptin receptor 
because of a nonsense point mutation in Lepr 208–210. 
These rats are hyperphagic and morbidly obese and 
have reduced energy expenditure, impaired glucose tol-
erance, impaired insulin sensitivity and stunted linear 
growth owing to lower activity of the GH–IGF1 axis 
and to hypothyroidism. Female and male rats that are 
homozygous for the mutation are infertile. In addition, 
and in contrast to the Zucker rat, the Koletsky rat devel-
ops hypertension starting at an age of 30 days211. Neither 
the obese Zucker rat nor the Koletsky rat is prone to 
developing diabetes mellitus.
The ZDF rat was derived through selective breeding 
of hyperglycaemic obese Zucker rats. ZDF rats carry an 
autosomal recessive defect in the β-cell transcription 
machinery that is inherited independently from the 
mutation in Lepr. The resulting animal model is one of 
obesity with a severe diabetic syndrome, with sustained 
and early-onset hyperglycaemia and progression to β-cell 
death, hypoinsulinaemia and premature death212.
Following adult-onset chronic hyperglycaemia and 
insulin resistance, the Otsuka Long–Evans Tokushima 
Fatty (OLETF) rat develops diabetes mellitus, with char-
acteristic symptoms such as polyuria and poly dipsia, 
owing to β-cell exhaustion. These rats also exhibit a 
mild hyperphagia-induced obesity213,214. The OLETF 
rats also lack the cholecystokinin (CCK) receptor type 
A, contributing to their phenotype. CCK is a gut- derived 
peptide hormone that functions as a peripheral satiation 
signal215, and experiments on the OLETF rat have been 
pivotal in unravelling the function of CCK in metab-
olism and have progressed our understanding of gut–
brain crosstalk. These rats also exhibit a behavioural 
phenotype of self-correcting energy balance; when pro-
vided with concomitant access to a HFD and running 
wheels, the OLETF rats greatly increase their energy 
expenditure and are consequently indistinguishable 
from non-mutant control rats with respect to food intake 
and adiposity216. These findings underline the complex 
role of gut–brain signals in behavioural aspects of energy 
homeostasis217 as well as the importance of using appro-
priate transgenic models to research the underlying 
mechanisms of obesity and diabetes mellitus.
Overall, monogenic animal models of metabolic 
diseases are valuable for understanding human- specific 
gene functions and monogenic forms of obesity, and 
they have emerged as central research tools in modern 
drug discovery research. Researchers frequently use 
the ob/ob mouse model on the C57BL/6J background 
to assess the potency of novel anti-obesity medications 
to overcome a strong hyperphagia-driven obese phe-
notype (for example, REF. 218). Furthermore, studies 
investigating whether leptin action is required as a 
cofactor for metabolic benefits of specific therapeu-
tics have used this model219. The db/db mouse on the 
C57BLKS/J background is often used in studies investi-
gating the efficacy of anti-diabetic drugs218. Frequently, 
however, researchers fail to sufficiently consider that 
these mouse models are based on a very specific recep-
tor mutation, while the patient populations for which 
these drug candidates are being designed cannot be 
reduced to a single locus.
The use of gene-editing tools to create targeted 
monogenic animal models to explore the physio logical 
role of specific genes has burgeoned in the past 20 years. 
Although this endeavour has taught us a great deal about 
the cellular and molecular underpinnings of energy 
homeostasis, it is becoming increasingly clear that met-
abolic characterization of transgenic animal models 
might be less predictive of the physiological function of 
the gene of interest than is often assumed. For exam-
ple, genetic manipulation could impose compensatory 
biological changes during development that in turn take 
over the function of an otherwise key gene. Exemplifying 
the predictive limitations of germline gene knockouts, 
mice deficient in glucagon-like peptide 1 receptor 
(GLP-1R) are protected from DIO and exhibit only 
mild defects in glucose tolerance. Taken at face value, 
these data imply that GLP-1R agonism would have lit-
tle to no metabolic benefits220,221. Yet, GLP-1R agonists 
belong to the currently best-in-class therapeutics for 
treating obesity and T2DM, exemplifying the hazards 
of determining gene function on the basis of germline 
transgenic models and also illustrating the possibility of 
overlooking relevant therapeutic utility222.
Despite this well-known phenomenon of genetic 
redundancy, we have still not described the majority of 
mammalian gene functions. Instead, genetic research 
has continued to focus on those molecular pathways 
that were already discovered before the sequencing 
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of the first mammalian genomes (human and mouse) 
at the beginning of the 21st century223. International 
consortia are currently undertaking unbiased systemic 
phenotyping screens of gene-targeted mutant mice to 
specifically explore new and pleiotropic gene functions 
of the ignored genes97. Studies have identified more 
than 50 genetic loci associated with phenotypic para-
meters of glucose homeostasis, metabolism or obesity 
in a systemic phenotyping screen of 27,000 mice from 
449 mutant lines224. These data suggest that we can 
expect that the number of monogenetic animal models 
for obesity and diabetes will dramatically increase over 
the next decade.
Polygenic models. Human obesity has a strong heredit-
able component. GWAS linking common genetic varia-
bility to specific traits (such as obesity) identified ~100 
obesity candidate-genes, including, for example, FTO225. 
Intriguingly, most of these obesity-associated genes are 
associated with neuronal processes, consistent with the 
hypothesis that obesity is a disease of the central nervous 
system226. In addition, the sheer (and increasing) num-
ber of genetic loci that have been associated with obesity 
emphasizes that common human obesity is a polygenic 
disease with a large degree of inter- individual heteroge-
neity. Therefore, polygenic obesity-prone rodent models 
are important to better capture the human condition.
As discussed above, the C57BL6/J is a polygenic 
obesity- prone mouse strain that is widely used in exper-
iments, as these mice develop hyperphagia-induced 
obesity when put into an obesogenic environment; how-
ever, several groups have observed heterogeneity in the 
response of C57BL6/J mice to a HFD. Approximately 
60% of C57BL6/J mice in an obesogenic environment 
will have an increase in body weight, whereas the others 
have a comparable body weight to control mice fed a 
standard diet. This finding, which is possibly a result of 
epigenetic differences, is reminiscent of the diverse range 
of obesity susceptibility among humans. We are able to 
distinguish between DIO responder and non-responder 
C57BL6/J mice at 6 weeks of age, when the two groups 
differ with regards to levels of plasma insulin and leptin 
as well as in insulin sensitivity227,228.
Analogous to C57BL6/J mice, only ~50% of outbred 
Sprague Dawley rats develop obesity on a HFD; the 
remainder are resistant to DIO229. When fed a low-fat 
chow diet, DIO-prone (DIO-P) rats eat and weigh about 
the same as DIO-resistant (DIO-R) rats, but when fed a 
HFD, DIO-P rats present increased feeding efficiency, 
hyperinsulinaemia and hyperleptinaemia as well as a 
rapid onset of obesity. Notably, compared with DIO-R 
rats, DIO-P rats have reduced central leptin and insu-
lin sensitivity before the inception of obesity230–232. The 
DIO-P and DIO-R phenotypes are inheritable, making 
it possible to generate stable DIO-P and DIO-R sub-
strains that reproduce many of the features of polygenic 
human obesity94.
The sand rat, which is actually a diurnal gerbil 
(Psammomys obesus), is an outbred polygenic model 
of nutrition-dependent early-onset obesity and associ-
ated diabetic sequelae. In its native semi-desert habitat, 
with access to a low-calorie plant-based diet, the sand 
rat is lean and normoglycaemic. In the laboratory set-
ting, however, with ad libitum access to an energy dense 
laboratory rodent diet, the sand rat becomes obese and 
rapidly develops hyperglycaemia followed by hallmark 
manifestation of T2DM such as severe hypoinsulinae-
mia, hyperlipidaemia and ketosis that are often observed 
within 3–4 weeks of birth233. Similar to the end-stage 
T2DM progression in humans, the diabetic sand rat suf-
fers from β-cell degradation, nephropathy, body weight 
loss and premature death234,235. On a cholesterol-rich diet, 
the sand rat also develops non-alcoholic steatohepatitis 
with morphological and functional consequences that 
are similar to the human pathology236. Through selective 
breeding, researchers have also created diabetes-prone 
and diabetes-resistant sand rat cohorts to study the 
interaction between diet and genes in the development 
of diabetes and obesity234.
The New Zealand Obese (NZO) mouse is another 
inbred polygenic strain that develops obesity and 
T2DM79. Adiposity in the NZO mouse is driven by a 
moderate hyperphagia, reduced energy expenditure and 
reduced voluntary activity. These effects are accompa-
nied by dysregulated leptin signalling and glycaemic 
disturbances related to both pancreatic and hepatic 
defects237,238. By the age of 4–5 weeks, NZO mice exhibit 
insulin resistance in brown adipose tissue and skeletal 
muscle239. Notably, the macronutrient composition of the 
diet is important for the diabetogenic phenotype240. NZO 
mice fed a carbohydrate- free diet remain normoglycae-
mic despite marked insulin resistance and obesity241. 
However, when switched to a carbohydrate-containing 
diet, there is a dramatic effect on the pancreatic islets 
including a loss of RAC-α serine/threonine-protein 
kinase (AKT) activation, decreased expression of glu-
cose transporter GLUT2 and reduction in several tran-
scription factors that are essential for insulin synthesis 
and β-cell integrity242. This makes the model suitable 
for assessing the ability of novel therapeutics to prevent 
carbohydrate-mediated β-cell failure243. Similar to what 
occurs in humans, the onset of T2DM in NZO mice 
decidedly depends on the degree of hepatosteatosis early 
in life. When the liver fat content is <10% at the age of 
10 weeks, NZO mice are protected from ensuing hyper-
glycaemia and β-cell loss244. Dietary interventions such 
as a moderate calorie restriction or intermittent fasting 
(fasting every other day) can protect NZO mice from 
hyperglycaemia. This effect is accompanied by reduced 
hepatic triglyceride and diacylglycerol concentrations, 
a decrease in protein kinase C-ε type (PKCε) activation 
and improved insulin sensitivity245.
The TALLYHO/Jng (TH) mouse is an inbred poly-
genic model of T2DM that exhibits moderate obesity. TH 
mice have reduced insulin-stimulated glucose uptake in 
adipose tissue and skeletal muscle and abnormal pancre-
atic morphology and function, symptoms that, in many 
aspects, resemble polygenic human T2DM246. Despite 
hyperinsulinaemia and obesity, female TH mice remain 
euglycaemic247. The molecular underpinnings of the 
diabetic phenotype might relate to lower levels of insu-
lin receptor substrate 1 (IRS-1) and impaired GLUT4 
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mobilization in the adipose tissue248. Moreover, male 
TH mice present drastically increased plasma triglyc-
eride levels as part of the diabetic phenotype247. Finally, 
the TH mouse displays reduced bone mineral density249, 
making it an interesting model for studying the interplay 
between T2DM and the skeleton.
The University of California (UC) Davis-T2DM 
(UCD-T2DM) rat model was created by crossing 
Sprague Dawley rats with adult-onset obesity and insu-
lin resistance with ZDF-lean rats that are wild-type for 
the leptin receptor but have a pancreatic β-cell and/or 
islet defect and that together result in the develop-
ment of overt T2DM with marked hyperglycaemia250. 
UCD-T2DM rats have impaired glucose-stimulated 
insulin secretion, and their fasting and fed glucose con-
centrations exceed 250 mg/dl and 450 mg/dl, respec-
tively, and their HbA1c is >7% within 3–4 months 
following diabetes onset. The rats develop T2DM on 
a low-fat, low-sugar diet, and both sexes are affected; 
however, the onset of diabetes is earlier in males 
(~4–8 months of age) than in females (~8–12 months 
of age). UCD-T2DM rats develop a number of compli-
cations of T2DM, including albuminuria250, defects in 
vertebral disc and bone structure and function251 and 
defects in brain and/or neuronal plasticity and metabo-
lism252. Because they are leptin-responsive, UCD-T2DM 
rats are fertile, unlike leptin- deficient ZDF rats. Chronic 
leptin administration normalizes fasting hyperglycae-
mia and lowers levels of HbA1c in UCD-T2DM rats253. 
Exogenous leptin administration also results in a 
reduction in agouti- related protein (AgRP) mRNA, an 
increase in pro- opiomelanocortin (POMC) mRNA in 
the hypothalamus, a decrease in hepatic gluco neogenic 
enzymes (glucose- 6-phosphatase (G-6-Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK)) and a 
reduction of endoplasmic reticulum stress in the liver, 
muscle, adipose tissue and pancreas253. Treatment with 
a GLP-1R agonist254, a peroxisome proliferator- activated 
receptor-γ (PPAR-γ) agonist255 or two types of bariatric 
surgery, ileal interposition256 and vertical sleeve gas-
trectomy257, delays the onset of T2DM in UCD-T2DM 
rats by 4 months or more (equivalent to >10 years in a 
human lifespan). Overall, the UCD-T2DM rat is a ver-
satile rodent model that can be used in the development 
and evaluation of novel strategies for the therapeutic 
management and prevention of T2DM and its sequelae.
In sum, it is without question that the greatest chal-
lenge when selecting an appropriate genetic model 
for metabolic studies is in ensuring that the model is 
appropriately tailored to the specific research question 
under investigation. For preclinical drug development 
programmes, employing susceptible polygenic models 
can be a good starting point to test compound efficacy 
and safety. For subsequent follow-up target validation of 
novel therapeutics, genetic loss-of-function models are 
the most relevant.
Rodent models for pancreatic β-cell dysfunction. The 
defining feature in the progression of T2DM is the decrease 
in β-cell function and β-cell number that ultimately leads 
to insufficient insulin production and secretion258,259. 
The mechanisms underpinning this β-cell failure are 
multifactorial (for example, environment and nutri-
tion) and include a complex genetic architecture260. 
Several polygenic rodent models of T2DM exist, but for 
most, the progression from insulin resistance to T2DM 
with β-cell failure can be secondary to obesity (such 
as with the TH mouse, sand rat and NZO mouse dis-
cussed above). By contrast, the Goto–Kakizaki (GK) rat 
is a non-overweight polygenic T2DM model261. GK rats 
have a neonatal β-cell mass deficit, and in adult animals, 
total β-cell mass is depleted by 50%262. Several distinct 
genetic lesions occur in GK rats including defects in 
β-cell metabolism and function. When combined with 
chronic hyperglycaemia, inflammation and oxidative 
stress, the consequence of defects in β-cell metabolism 
and function is a perturbed islet architecture and loss of 
β-cell mass, which makes GK rats an established model 
to investigate the interconnection between β-cell failure 
and T2DM263.
To understand specific molecular pathways that 
underpin β-cell dysfunction, the use of monogenic 
rodent models is invaluable. These models usually have 
mutations in genes that encode transcription factors 
important for β-cell identity or protein components of 
machineries that regulate glucose sensing or insulin secre-
tion. The Akita mouse, for example, carries a spontaneous 
mutation in Ins2 that causes the accumulation of misfolded 
proinsulin, which leads to endoplasmic reticulum stress 
and ultimately loss of β-cells264–266.
Other models of β-cell dysfunction target the matu-
rity onset diabetes of the young (MODY) — an umbrella 
term for several hereditary forms of diabetes mellitus 
that develop from spontaneous mutations in essen-
tial β-cell-specific genes and that account for ~1% of 
all diabetic cases in humans267. MODYs exemplify the 
utility of personalized therapy. Mutations in KCNJ11, 
for example, lead to the transcription of a defective 
potassium channel that can cause neonatal diabetes 
in humans. If detected, this particular MODY can 
be effectively treated with sulfonylurea267. Similarly, 
transgenic mice overexpressing the same defective 
potassium channel exhibit hyperglycaemia and β-cell 
de- differentiation, which can also be reversed by 
treatment with sulfonylurea or insulin therapy268–271. 
Mutations in Gck (which result in MODY2 in humans) 
and Hnf1a (which result in MODY3 in humans) induce 
impaired glucose tolerance and deficient insulin secre-
tion in mice, respectively272–275. In humans, MODY4 is 
caused by a heterozygous mutation in PDX1, which is 
essential for β-cell development and function276. Pdx1 
hetero zygous mice develop hyperglycaemia in adult-
hood, and β-cell-specific Pdx1 deletion induces loss of 
β-cell identity277,278.
A similar phenotype to that of MODYs occurs in 
Foxa2–Venus Fusion (FVF), Pdx1–BFP Fusion (PBF) 
double homozygous (FVFPBFDHom) reporter mice, in 
which Foxa2 and Pdx1 are genetically fused with fluo-
rescent proteins. In these mice, impaired β-cell matu-
ration and loss of identity trigger transdifferentiation 
of β-cells into other endocrine cell types that conse-
quently decreases β-cell number and causes diabetes279. 
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Interestingly, female FVFPBFDHom mice are protected 
from diabetes mellitus; however, during pregnancy, 
they develop gestational diabetes. Therefore, 
FVFPBFDHom mice provide a sexually dimorphic dia-
betic model with the ability of β-cell tracking due to 
the fused fluorescent proteins.
Mechanical or chemical induction
Obesity. Early research on the role of the brain in obe-
sity examined the effects of lesions targeting different 
regions of the hypothalamus. These efforts uncovered 
the ventromedial hypothalamus as a pivotal satiety 
centre and the lateral hypothalamus as an eating cen-
tre280. The effects of such lesions were profound and 
led to the recognition of the hypothalamus as a key 
brain area with regards to influencing metabolism. For 
example, lesions in the ventromedial hypothalamus 
lead to hyperphagia, weight gain and adiposity, despite 
increases in circulating leptin. A similar phenotype can 
be induced by physically cutting — and therefore sev-
ering — ventromedial hypothalamus axonal connec-
tions, by stimulating the ventromedial hypothalamus 
via locally implanted electrodes or by locally injecting 
procaine or other neuronal blockers. Each of these pro-
cedures results in an immediate phenotype of ravenous 
overeating and weight gain.
Although these interventions might appear some-
what crude, in some studies, the physiological conse-
quences observed were rather sophisticated. In rats, 
lesions in the lateral hypothalamic area reduced food 
intake but did not disrupt the ability of the animal to 
regulate food intake in a fasting and/or feeding para-
digm. Rather, the lesioning altered the settling point for 
body mass, or adiposity281. Today, targeted genetic dis-
ruption of certain brain regions or specific cells in the 
brain is often preferred over the lesion approach, which 
influences not only all neurons in the impacted area but 
also neuronal connectivity between brain regions78,280.
Diabetes mellitus. Type 1 diabetes mellitus (T1DM) and 
T2DM have different causes, but both ultimately lead to 
pancreatic β-cell dysfunction. Damaging the pancreas 
chemically or mechanically can induce experimental 
diabetes mellitus. Pancreatic damage can be achieved by 
surgically removing parts of or all of the pancreatic tissue 
(pancreatectomy) to reduce or fully ablate endogenous 
insulin production282. The benefit of this method is the 
lack of toxic adverse effects (compared with diabetogenic 
drugs) on other organs. However, a prerequisite for spe-
cialized training and surgical equipment, as well as the 
confounding effects of eradicating exocrine pancreatic 
digestive enzymes and other islet hormones, limits the 
widespread use of pancreatectomy.
Chemical approaches, such as the use of the diabe-
togenic drugs streptozotocin or alloxan, to target the 
insulin-secreting β-cells are also available. Both drugs 
are cytotoxic glucose analogues that, owing to their high 
affinity for the GLUT2 transporter, primarily target 
β-cells. Streptozotocin is favoured over alloxan because 
it is more stable and less toxic. Researchers initially used 
these drugs to elicit a stable model of T1DM (that is, they 
were used to destroy all β-cells), but low doses elicit only 
partial β-cell loss, more reminiscent of T2DM. A popular 
approach is to combine HFD feeding with a subsequent 
injection of a low dose (~30–40 mg/kg intraperitone-
ally) of streptozotocin to model the transition from the 
pre-diabetic insulin-resistant state to overt T2DM283. The 
key advantage of this nongenetic model is that research-
ers can customize it to resemble the slow pathogenesis 
of T2DM that occurs in most humans, encompassing 
the slow development from adult-onset DIO to glucose 
intolerance, insulin resistance, the resulting compensa-
tory insulin release and finally streptozotocin-induced 
partial β-cell death.
To achieve a slow pathogenesis of T2DM, young adult 
mice284 or rats285 are fed a high-fat or Western diet to elicit 
DIO and insulin resistance. Single or multiple injections 
with low-dose streptozotocin (~30–40 mg/kg intraperi-
toneally) then elicit partial loss of β-cells, which results 
in hypoinsulinaemia and hyperglycaemia. Protocols are 
being continuously refined and likely differ between spe-
cies and even strains283. The HFD streptozotocin rat is 
sensitive to metformin, further demonstrating the utility 
of this model285. Downsides of streptozotocin treatment 
include liver and kidney toxicity and mild carcinogenic 
adverse effects (TABLE 1).
Energy balance measurements in rodents
Obesity is the consequence of a positive energy imbalance 
of energy intake over energy expenditure. To accurately 
calculate energy intake, the ingestion of a standardized 
diet, as well as the energy resorption efficiency, is meas-
ured. For the latter, the energy content of the faeces and 
food are quantified over time, and the difference between 
the calorie intake and the energy that is lost with faeces 
is then considered the metabolized energy. Of note, this 
process neglects the energy that is lost with urine and 
combustible gases. In humans, measurements of energy 
intake over sufficiently long periods are very involved 
and costly. Techniques to measure energy expenditure 
in humans vary286, but they are also very elaborate and 
are usually performed in laboratory settings.
The small size of the laboratory mouse has enabled 
researchers to develop several commercial systems that 
can monitor food and drink consumption as well as 
energy expenditure over long periods, with high through-
put, resolution and accuracy and in conditions that closely 
approximate regular mouse housing. These systems use 
indirect calorimetry to determine energy expenditure on 
the basis of the amount of oxygen consumed and carbon 
dioxide produced287.
To correctly interpret mouse energy expenditure 
data, one must conduct a careful and appropriate analy-
sis. Researchers have been intensely discussing the best 
methods to normalize the metabolic rate of laboratory 
mice for more than 50 years. The various approaches, 
some of which have been used more than others, include 
the direct comparison of uncorrected values (kcal per 
hour), correction by lean body mass, correction by 
body weight, correction by the body weight raised to the 
power of 0.75 or, as more recently suggested, by analysis 
of covariance (ANCOVA)287–289. The current consensus 
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is that analysis of energy expenditure data by use of 
ANCOVA, with body weight and body composition as 
covariants, is the most appropriate way to analyse energy 
expenditure287,289,290.
In line with this notion, the correction of energy 
expenditure data by body weight should be avoided, 
as the metabolic rate does not increase in direct linear 
proportion to body weight (for example, the basal met-
abolic rate of a mouse weighing 50 g is not twice as great 
as the basal metabolic rate of a mouse weighing 25 g). 
Correction of energy expenditure by the body weight 
raised to the power of 0.75 seems more appropriate given 
that the basal metabolic rate of different species can quite 
accurately be predicted using this formula; however, the 
correction of energy expenditure by use of the so-called 
metabolic factor (BW0.75) is suitable for the comparison 
of only different species and not for the comparison of 
two cohorts of mice. In addition, the regression line 
of such a normalization typically does not go through 
the zero intercept, a clear indication that this correction 
is inappropriate. Correction by lean body mass is also 
not advisable because such a correction assumes that 
the amount of fat mass is not contributing to metabolic 
rate. Brown adipose tissue in mice, however, can under 
certain circumstances account for up to 60% of the basal 
metabolic rate287, and the correction of energy expendi-
ture by lean body mass leads to spurious results by over-
compensating for the lean mass effect287,291. The preferred 
method to best express changes in energy expenditure, 
in a way that takes differences in body weight and body 
composition into account, is thus the ANCOVA287,289, and 
there are step-by-step guides available to help scientists 
with such an analysis290.
Other considerations and limitations
A myriad of factors affect animal experiments. Men elicit 
a greater stress response in mice than women292, likely 
confounding feeding behaviour. Rodents from different 
production facilities (for example, Jackson Laboratory 
and Taconic) have unique gut microbiotas293, perhaps con-
tributing to differences in their susceptibility to DIO and 
related diabetic complications293. Similarly, cage position 
within a rack of cages, single versus group housing, the 
skill level of the researcher, ambient room temperature 
or the type of cage bedding can all affect experimental 
outcomes.
Researchers must carefully consider the primary end 
point of each experiment. For example, if body weight is 
the key metric, researchers should limit or abstain from 
performing noninvasive procedures such as a glucose 
tolerance test. The stress and the fasting period inherent 
to these procedures confound weight gain. Researchers 
should also be aware of strain differences in rats and 
mice with regards to the susceptibility to stress294,295. 
Even within a strain, such as the widely used C57BL/6J 
mouse, there are responders and non-responders to 
stress296. When characterizing novel rodent models 
that are hypothesized to have a metabolic phenotype, a 
good idea is to conduct an initial experiment in which 
only food intake and body weight progression are 
measured weekly until at least middle age. Obtaining 
high- quality data for body weight and food intake is 
a pivotal foundation for subsequent experiments in 
metabolic research.
We believe there are several factors that researchers 
should consider when conducting obesity and diabetes 
mellitus research in rodents (FIG. 2). Although our list is 
by no means an exhaustive, it demonstrates the com-
plexity and interconnectedness of the myriad of factors 
that can confound experimental outcomes. Although 
it is impossible to control for everything, researchers 
should accurately detail all experimental conditions and 
methods to allow for better interpretation of the results 
and, importantly, for better reproducibility.
Another concern pertains to control mice. Compared 
with free-living mice in the wild, laboratory control 
mice with ad libitum access to food are sedentary, over-
weight, glucose intolerant and tend to die at a younger 
age297. Comparisons between mice with DIO and con-
trol mice might be analogous to investigating the genetic 
cause of obesity-resistance by comparing humans who 
are overweight or obese. This potential problem with 
control mice could explain why the use of DIO diets that 
have 40% to 60% of total energy from fat is so prevalent, 
as this might be necessary to achieve divergent weight 
gains. With free access to running wheels, C57BL/6J mice 
voluntarily run 5–10 km per day298,299. As is the case with 
humans300, mice get health benefits from regular physical 
activity including weight loss, decreased adiposity and 
improved insulin sensitivity301,302. Physical activity might 
also affect the epigenome over several generations303. An 
enriched physical and social cage environment alone 
improves leptin sensitivity and energy expenditure in 
mice, independent of physical activity304,305. Overall, 
these data suggest that with standard mouse husbandry, 
chow-fed laboratory mice are not the ideal healthy and 
lean control group for meaningful obesity research.
Lastly, while rodents recapitulate many aspects 
of human metabolism, researchers should be aware of 
key species differences in basal metabolic rate, feeding 
behaviour, fecundity, immune system306 and gut micro-
biota293. Another important difference is the primary site 
of glucose disposal: in humans, this is skeletal muscle, 
while in rodents, the primary site is the liver, which is 
reflected by the relative liver weight being ~2.5 times 
greater in rats and mice than in humans307.
Large animal models
The need for a large model that allows chronic cannula-
tion of vessels and access to anatomic regions not possible 
in humans (for example, the hepatic portal vein, hepatic 
and renal veins or cerebroventricles) has greatly increased 
as new hypotheses developed in non-mammalian organ-
isms and rodents require examination under conditions 
closer to human biology. Many metabolic studies on dogs 
historically used non-selected animals available from 
dealers, such as studies of insulin entry into308 and action 
within the brain309,310. Since these early studies, however, 
researchers have developed mongrel hound models that 
consistently develop overweight and/or obesity, pre- 
diabetes or low-dose-streptozotocin-induced diabetes 
mellitus within a reasonable period of time311–313.
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Overweight can be induced in dogs within a 
4–12-week period by providing excess amounts of die-
tary energy in various forms: a standard diet of meat 
and chow314; a meat and chow diet supplemented with 
fat315,316; or commercially prepared diets with either high-
fat or high-fructose content or both317. An increase in 
energy intake is most evident during the first 1–2 weeks 
on these supplemented diets, but hyperphagia is main-
tained throughout the time the animals have free access 
to the diets314,315,317. Elevated fasting glucose and insu-
lin concentrations are not observed in these models, 
but metabolic defects are clearly evident in all of them, 
despite modest increases in body weight. MRI studies 
identified increased visceral, subcutaneous and total 
adipose tissue mass on the high-fat, high-fructose 
diet (HFFD)318 and on a HFD315. The increase of body 
fat in mongrel dogs fed a HFD is inversely correlated 
with insulin transport into the brain316, an indication 
of increased insulin resistance at the blood–brain bar-
rier319. Dogs fed the HFFD have elevated glycaemic 
excursions during oral glucose tolerance tests320, and 
there is no change in the areas under the curve of insulin, 
indicating a β-cell defect. Moreover, after 10 weeks on 
the HFFD, dogs have a decrease in the glucose infusion 
rate required to maintain euglycaemia under hyper-
insulinaemic– euglycaemic clamp conditions, indicating 
a decrease in insulin sensitivity320.
Older and more obese dogs are prone to exhibit 
insulin resistance, accompanied by postprandial hyper-
glycaemia and hyperlipidaemia, but fasting hypergly-
caemia is rare321,322. Hyperinsulinaemia in both the 
fasting and fed state is common in these dogs, and this is 
apparently sufficient to maintain normoglycaemia in the 
fasting state, although not after feeding. A small percent-
age of dogs (~1%) spontaneously develop T1DM, but 
spontaneous T2DM is uncommon323, perhaps because 
of the capacity of the β-cell to compensate for insulin 
resistance268. As with rodents, researchers can induce dia-
betes mellitus in dogs with pancreatectomy or with the 
use of alloxan and/or streptozotocin313,324–326. The advan-
tage of the use of diabetogenic drugs is that the dose 
can be carefully titrated, which results in the main-
tenance of some insulin secretion. By combining a 
diet that includes excessive amounts of energy with 
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Figure 2 | Important experimental parameters and potential confounders of experimental outcomes in obesity and 
diabetes research and their interrelatedness. Countless factors influence experimental o tcomes when using a imal 
models, and what is enumerated here is by no means a complete list. This figure is one depiction of the multifactorial and 
interconnected genetic and environmental matrix that makes it virtually impossible to design the perfect experiment.  
For example, single-housing mice to obtain more accurate food intake data introduces a stress that in turn affects food 
intake. The severity of this stress response is both strain-specific and sex-dependent. What is important is to be aware of 
these challenges and to control for them in the most optimal manner. It is equally, if not more, important to accurately and 
comprehensively detail all experimental conditions in research papers, as these have bearing on the interpretation and 
reproducibility of the published results. DIO, diet-induced obesity.
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diabetogenic drugs, researchers have developed a canine 
model of pre- diabetes and can create a model of T2DM. 
This dog model allows invasive measures and assessments 
not possible in humans or rodent models. Moreover, in 
times of metabolic stress, such as pregnancy, researchers 
can induce pre-diabetes and diabetes mellitus by feeding 
dogs solely on a HFFD327,328.
The dog provides a useful model for examining the 
metabolic effects of overweight, obesity and diabetes 
mellitus, as well as for testing interventions for the man-
agement of these conditions. The canine model is espe-
cially powerful in allowing quantification of liver glucose 
uptake, which is impossible to assess directly in humans 
or small animal models. Being able to assess liver glucose 
uptake is particularly relevant because during normal 
meal feeding, the liver exhibits net glucose uptake for at 
least two-thirds of the day329. Because the dog absorbs 
a meal more slowly than a human330, examination of 
repeated meal responses within a day is not possible, but 
all other aspects of absorption and glucose disposition 
appear to reflect those in the human.
The pig is another large animal model used for trans-
lational studies in research on obesity and diabetes melli-
tus. Obesity in pigs is routinely induced by high-energy 
high-fat and/or high-carbohydrate diets331,332. Minipig 
lines, such as Ossabaw, Yucatan or Göttingen minipigs, 
are most widely used because they can be reared to 
adulthood at reasonable costs. Dietary supplementation 
of cholesterol provokes pronounced dyslipidaemia (ele-
vated cholesterol, LDL cholesterol and HDL cholesterol). 
Although impaired glucose tolerance is inconsistently 
observed, DIO in domestic or minipigs does not lead to 
an overt diabetic phenotype332. Rather, this requires addi-
tional manipulations, such as damage of β-cells by strep-
tozotocin or alloxan or impairment of β-cell function by 
specific genetic modifications.
Genetic engineering of pigs has been remarka-
bly refined333 and represents an approach of generat-
ing tailored large animal models for diabetes mellitus 
research (TABLE 2). Currently available pre-diabetic and 
diabetic models include transgenic pigs expressing a 
dominant-negative glucose-dependent insulinotropic 
polypeptide receptor (GIPR)334 and transgenic pigs 
expressing mutant insulin335 or hepatocyte nuclear factor 
1α (HNF1A)336. In addition, researchers have generated a 
number of genetically engineered pig models with dyslipi-
daemia and atherosclerosis337, facilitating studies of poten-
tial interactions between these metabolic disturbances.
On the basis of their anatomical and physiological 
similarities to humans, their high fertility and easy main-
tenance, the possibility of dietary and surgical interven-
tions and the efficient and specific genetic modifications, 
pigs are promising models to overcome gaps between 
proof-of-concept models and clinical studies in obesity 
and diabetes mellitus research. In addition, pigs might 
serve as tissue donors for β-cell replacement therapies of 
Table 2 | Examples of genetically engineered pig models for diabetes and dyslipidaemia research
Genetic modification and/or mechanism Phenotypic consequences Potential applications
Expression of a dominant-negative GIPR in 
β-cells334
Impaired incretin effect; reduced glucose tolerance 
and insulin secretion; progressive reduction of 
β-cell mass334
Screening for biomarkers of prediabetes382; 
testing of incretin-based therapies383
Expression of mutant insulin-C94Y in β-cells335 Permanent neonatal diabetes mellitus; impaired 
insulin secretion; β-cell apoptosis; reduced growth; 
cataract335; reduced vascularization and pericyte 
investment in the myocardium384; retinal changes 
similar to diabetic retinopathy385
Testing of insulin or β-cell replacement 
therapies; treatments to prevent endoplasmic 
reticulum stress; studying effects of chronic 
hyperglycaemia on different organ systems and 
organ crosstalk332,386,387
Ubiquitous expression of a 
dominant-negative human HNF1A336
Persistent diabetes mellitus; abnormal pancreatic 
islet morphogenesis; immature renal development; 
pathological alterations of the kidneys and liver336
Studying diabetic complications*388
Liver-specific expression of the PCSK9-D374Y 
gain-of-function mutant389
Reduced hepatic LDL cholesterol receptor levels; 
impaired LDL cholesterol clearance; severe hyper-
cholesterolaemia; spontaneous development of 
atherosclerotic lesions389
Testing of therapeutic compounds and imaging 
and intravascular devices389; evaluating the role 
of hyperglycaemia in atherogenesis390
Expression of human ApoC-III (REF. 391) Increased plasma triglyceride levels; delayed 
clearance of plasma triglyceride; reduced 
lipoprotein lipase activity391
Understanding the roles of ApoC-III in 
lipid metabolism and of triglycerides 
in atherosclerosis; evaluating drugs for 
hypertriglyceridemia391
Expression of human ApoA392,393 High plasma levels of human ApoA393 Evaluating the pharmacology and efficacy of 
new drugs for atherosclerosis393
Knockout of the gene encoding LDL 
receptor394,395
Moderate (LDLR+/–) or severe (LDLR–/–) increase 
in total and LDL cholesterol on a standard diet; 
more severe on a high-fat, high-cholesterol diet21; 
atherosclerotic lesions in the coronary arteries and 
abdominal aorta (LDLR–/–)394,395
Developing and testing novel detection and 
treatment strategies for coronary and aortic 
atherosclerosis and its complications394–396
Overexpression of LDL-PLA(2)397 Increased postprandial plasma triglyceride levels; 
increased expression of pro-inflammatory genes in 
peripheral blood mononuclear cells397
Studying the consequences of elevated 
circulating LDL-PLA(2) levels; testing 
LDL-PLA(2) inhibitors397
ApoA, apolipoprotein(a); ApoC-III, apolipoprotein C-III; GIPR, glucose-dependent insulinotropic polypeptide receptor; HNF1A, hepatocyte nuclear factor 1α; 
LDL-PLA(2), LDL-associated phospholipase A2; PCSK9, proprotein convertase subtilisin/kexin type 9. *The pathological changes in this model may be caused by 
expression of mutant HNF1A and not be a consequence of diabetes mellitus.
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insulin-dependent diabetes mellitus338,339 or as a source 
of reporter islets for ex vivo studies of β-cell matura-
tion, proliferation and heterogeneity340. While pigs are 
increasingly used as models for obesity and diabetes 
mellitus research, dogs remain an important model in 
this field, particularly for studies involving oral admin-
istration of compounds, which is much easier in dogs 
than in pigs (TABLE 3).
Non-human primates
A long history of studying non-human primates for 
translational research in metabolic diseases, including 
hyperlipidaemia, atherosclerosis, T2DM, hypertension 
and fatty liver disease, exists. The most commonly used 
species in metabolic disease research include rhesus 
macaques (Macaca mulatta), cynomolgus monkeys 
(Macaca fascicularis), baboons (Papio species), African 
Green Monkeys (Chlorocebus species) and common 
marmosets (Callithrix jacchus), although a number of 
other species have been used341. With respect to met-
abolic physiology, non-human primates differ from 
rodents and are more similar to humans in the major 
site of de novo lipogenesis (adipose tissue versus liver), 
in the major circulating lipoprotein subclasses and in the 
physiology of thermogenesis and utilization of insulin- 
meditated glucose utilization341. Rhesus macaques have 
been useful in the translation of studies on the regulation 
of ingestive behaviour by gastrointestinal peptides such 
as glucagon-like peptide 1 (REF. 342) and peptide YY343 
as well as on the physiology and pharmacokinetics of 
leptin administration, in models ranging from rodents 
to primates344,345. Rhesus macaques have also proved val-
uable for investigations into the role of the autonomic 
nervous system in postprandial insulin secretion346 and 
in the regulation of glucagon secretion during insulin- 
induced hypoglycaemia347, as well in studies of com-
pensatory insulin secretion in glucocorticoid-induced 
insulin resistance348. Studies in non-human primates 
have led directly to translational studies confirming the 
same mechanisms in humans349,350. Studies of long-term 
energy restriction in aged rhesus macaques have also 
been important for translating the effects of limiting 
calorie intake, including extending lifespan and improv-
ing glucose and lipid metabolism, originally reported in 
rodents to primates351–355.
Diabetes mellitus secondary to insulin resistance 
and to inadequate β-cell and/or islet compensation has 
been reported to spontaneously develop in a number 
of captive non-human primate species341. Data show 
a high prevalence of T2DM in captive Macaca nigra356 
and a substantial prevalence of T2DM in captive rhesus 
macaques357. The progression of obesity accompanied by 
the progression from insulin resistance to β-cell failure 
and overt diabetes mellitus with ageing in captive rhesus 
macaques has been well characterized in longitudinal 
studies and is similar to the progression observed in 
cross-sectional studies in humans358. The presence of 
islet amyloidosis characteristic of T2DM in humans is 
also observed in diabetic monkeys, implicating a simi-
lar aetiology of islet lesions in monkeys and humans359. 
Diabetes mellitus associated with insulin resistance can 
be induced by administering nicotinic acid to baboons 
with reduced β-cell mass produced with a low dose 
(40 mg/kg) of intravenous streptozotocin360; however, 
this model is less representative of T2DM in humans 
owing to the chemically induced islet lesion.
Diet-induced models of non-human primate meta-
bolic disease are commonly used to accelerate the devel-
opment of the metabolic disease phenotype observed in 
captive non-human primate species that are fed a stand-
ard low-fat, low-sugar laboratory primate diet. Examples 
of diet-induced models include a baboon (Papio hama-
dryas) model that is exposed to a high-fat, high-sugar 
diet for 8 weeks, which increases fat mass and plasma 
Table 3 | Major advantages of dog and pig models for obesity and diabetes mellitus research
Parameter Dog Pig
Monogastric omnivore, approaching the size and weight of humans over a wide 
range of developmental periods
Yes Yes
High fecundity (8–14 offspring per litter) Yes Yes
Similar pancreas and islet structure, total β-cell mass, ratio of β-cell mass to 
body mass and β-cell replication capacity as in humans
Yes Yes
Suitable for testing medical devices (for example, bioartificial pancreas) and 
surgical techniques (for example, bariatric surgery)
Yes Yes
Pharmacokinetics of orally or subcutaneously administered compounds similar 
to humans
Yes (oral, 
subcutaneous)
Yes 
(subcutaneous)
Placement of permanent catheters allows physiological tests and repeated 
blood sampling without anaesthesia or stress
Yes Yes
Existing protocols for diet-induced obesity and diet-induced atherosclerosis Yes 
(diet-induced 
obesity)
Yes (diet-induced 
obesity, 
diet-induced 
atherosclerosis)
Diet-induced glucose intolerance Yes Yes
Genetic engineering is well established – Yes
Well-established model for assessment of hepatic glucose metabolism, 
including hepatic glucose uptake
Yes –
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triglycerides and reduces circulating adiponectin con-
centrations361. Marmosets (C. jacchus) fed a HFD or a 
high-sugar diet have also been studied as a non- human 
primate model of metabolic disease362. A Japanese 
macaque model has been used to investigate the effects 
of diet-induced maternal obesity and of metabolic per-
turbations during pregnancy on offspring341,363,364. In rhe-
sus macaques, additional consumption of 300 kcal per 
day from flavoured fructose-sweetened beverages for 
up to 1 year results in the induction of many of the fea-
tures of the metabolic syndrome including the following: 
increased body weight and fat mass; insulin resistance 
assessed by intravenous glucose tolerance tests; dyslip-
idaemia with hypertriglyceridaemia; decreased HDL 
cholesterol; increased apolipoprotein B, apolipoprotein 
C-III and apolipoprotein E; and decreased adiponec-
tin365. A subset of these animals develops overt diabetes 
mellitus over the course of a year on the dietary regi-
men365. Interestingly, supplementation with a high dose 
(4 g per day) of omega-3 fatty acids from fish oil largely 
prevents the dyslipidaemia (as defined by an increase in 
triglycerides and apolipoprotein C-III) and the develop-
ment of insulin resistance over a period of 6 months in 
the fructose- fed rhesus macaque model366.
Dietary fructose also results in hepatic steatosis and 
inflammation in Old World monkeys367 and increases 
liver triglyceride and cholesterol content in rhesus 
macaques. Studies investigating the pathogenesis of fatty 
liver disease have also been performed in baboons and 
marmosets368–370. Importantly, DIO non-human primate 
models have proved valuable in evaluating the therapeu-
tic potential and/or safety of a number of interventions, 
including tyrosine-protein phosphatase non-receptor 
type 1 antisense oligonucleotides371, fibroblast growth 
factor 21372,373, glucagon-like peptide 1 agonists374, 
omega-3 fatty acids366, melanocortin receptor 4 ago-
nists375, tropomyosin receptor kinase B agonism376 and 
oxytocin administration377, in the treatment of obesity, 
insulin resistance and obesity-related metabolic diseases.
Diet-induced non-human primate models might soon 
be used to investigate the relationship between metabolic 
dysfunction, cognitive decline and dementia (including 
Alzheimer disease). Researchers are becoming increas-
ingly aware that both insulin resistance and diabetes 
mellitus are risk factors for cognitive impairment and an 
age-associated decline in cognition. The decline of cog-
nitive function in aged non-human primates has been 
well described378–380, and there is evidence that feeding a 
high-fat, high-sugar diet activates pathways involved in 
oxidative stress, apoptosis and inflammation in the cortex 
of middle-aged male rhesus macaques381. Research per-
formed in non-human primates enables the study of both 
cognitive function and markers of synaptic morphology 
and plasticity in the same animal. Performing these types 
of studies in non-human primates with diet-induced 
metabolic dysfunction, including dyslipidaemia, insulin 
resistance and T2DM, will be important in understand-
ing the effect of dietary components (both harmful and 
protective) and their metabolic consequences in the aeti-
ology, prevention and treatment of cognitive decline and 
dementia in humans.
Important advantages of non-human primate mod-
els include their close genetic relationship to humans 
and physiological similarity to humans. The baboon and 
rhesus macaque genomes have been sequenced, and this 
information can be used in target identification and val-
idation studies. Approaches used in the metabolic evalu-
ation of non-human primates include hyperinsulinaemic 
and hypoglycaemic clamps347, modelled intravenous 
glucose tolerance tests and indirect calorimetry365. In 
addition, their relatively larger size compared with the 
earlier mentioned models, and their anatomical similar-
ity to humans, make non-human primates particularly 
suitable for studies using advanced imaging techniques, 
including DXA, ultrasonography, PET and functional 
MRI. Another advantage of studies in non-human pri-
mates compared with humans is that adherence to diet 
and pharmacological interventions can be closely con-
trolled, whereas in free-living human studies, compli-
ance with dietary and treatment regimens is generally 
quite poor. In addition, researchers can conduct sequen-
tial biopsies of tissues including liver and intra -abdominal 
adipose tissue in studies of non-human primates. By 
contrast, in humans, these samples can be obtained in 
cross-sectional studies at only a single time point dur-
ing elective abdominal or bariatric surgery, which seri-
ously limits the selection of study participants as well as 
the ability to assess the effects of different interventions. 
Terminal collection of tissues such as brain (hypothala-
mus), kidney and pancreas for islet studies is also possible 
in non- human primate studies. The disadvantages of using 
non-human primates versus other models include the lim-
ited number of animals available for study, the expense of 
maintaining non-human primate colonies and the limited 
number of facilities that provide support for non-human 
primate research (for example, the seven National Primate 
Research Centers supported by the NIH).
In summary, non-human primates represent a valu-
able and physiologically relevant model and serve as a 
critical translational bridge between basic studies per-
formed in rodent models and clinical studies in humans. 
Given the substantial cost of conducting clinical trials in 
humans, studies in non-human primate models repre-
sent a cost- effective avenue for evaluating the efficacy 
and safety of novel therapeutic strategies targeting met-
abolic diseases, including dyslipidaemia, atherosclerosis, 
T2DM, hepatic steatosis and potentially cognitive dys-
function and dementia, before taking these therapies into 
clinical trials.
Conclusions
The existing therapeutic approaches to treat diabetes 
mellitus and obesity, which are saving millions of patient 
lives every day, were discovered, validated and opti-
mized in animal models. More sophisticated organoids 
are becoming available and offer useful complementary 
models for selected scientific questions, but so far, the 
models cannot replace mammalian models to study food 
intake, nutrient portioning, body fat distribution, sys-
temic glucose metabolism, brain control over metabolic 
fluxes, exercise metabolism or many other key aspects of 
metabolic health and disease.
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